They further confirmed the presence of dual molecular profiles of pulmonary LCNEC with an SCLC-subtype with mutations in RB1, TP53, MYCL amplification, and alterations in the PI3K/AKT/mTOR pathway; NSCLC-subtype with mutations in SKT-11, KEAP, and KRAS. This evidence concerns the gene MYCL and large cell neuroendocrine carcinoma.